TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21254 DO - 10.3322/caac.21254 ID - Siegel2015 ER - TY - JOUR AU - Millot, F. AU - Traore, P. AU - Guilhot, J. AU - Nelken, B. AU - Leblanc, T. AU - Leverger, G. PY - 2005 DA - 2005// TI - Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia JO - Pediatrics VL - 116 UR - https://doi.org/10.1542/peds.2004-2473 DO - 10.1542/peds.2004-2473 ID - Millot2005 ER - TY - JOUR AU - Faderl, S. AU - Talpaz, M. AU - Estrov, Z. AU - O’Brien, S. AU - Kurzrock, R. AU - Kantarjian, H. M. PY - 1999 DA - 1999// TI - The biology of chronic myeloid leukemia JO - N Engl J Med VL - 341 UR - https://doi.org/10.1056/NEJM199907153410306 DO - 10.1056/NEJM199907153410306 ID - Faderl1999 ER - TY - JOUR AU - Derderian, P. M. AU - Kantarjian, H. M. AU - Talpaz, M. AU - O'Brien, S. AU - Cork, A. AU - Estey, E. PY - 1993 DA - 1993// TI - Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis JO - Am J Med VL - 94 UR - https://doi.org/10.1016/0002-9343(93)90122-6 DO - 10.1016/0002-9343(93)90122-6 ID - Derderian1993 ER - TY - JOUR AU - Kantarjian, H. M. AU - Keating, M. J. AU - Talpaz, M. AU - Walters, R. S. AU - Smith, T. L. AU - Cork, A. PY - 1987 DA - 1987// TI - Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients JO - Am J Med VL - 83 UR - https://doi.org/10.1016/0002-9343(87)90754-6 DO - 10.1016/0002-9343(87)90754-6 ID - Kantarjian1987 ER - TY - JOUR AU - Helhmann, R. PY - 2012 DA - 2012// TI - How I, treat CML blast crisis JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-03-380147 DO - 10.1182/blood-2012-03-380147 ID - Helhmann2012 ER - TY - BOOK AU - Swerdlow, S. H. AU - Campo, E. AU - Harris, N. L. AU - Jaffe, E. S. AU - Pileri, S. A. AU - Stein, H. PY - 2008 DA - 2008// TI - WHO classification of tumours of haematopoietic and lymphoid tissue PB - International Agency for Research on Cancer CY - Lyon ID - Swerdlow2008 ER - TY - JOUR AU - Groschel, S. AU - Sanders, M. A. AU - Hoogenboezem, R. AU - Wit, E. AU - Bouwman, B. A. AU - Erpelinck, C. PY - 2014 DA - 2014// TI - A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia JO - Cell VL - 157 UR - https://doi.org/10.1016/j.cell.2014.02.019 DO - 10.1016/j.cell.2014.02.019 ID - Groschel2014 ER - TY - JOUR AU - Yamazaki, H. AU - Suzuki, M. AU - Otsuki, A. AU - Shimizu, R. AU - Bresnick, E. H. AU - Engel, J. D. AU - Yamamoto, M. PY - 2014 DA - 2014// TI - A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression JO - Cancer Cell VL - 25 UR - https://doi.org/10.1016/j.ccr.2014.02.008 DO - 10.1016/j.ccr.2014.02.008 ID - Yamazaki2014 ER - TY - JOUR AU - Ogawa, S. AU - Kurokawa, M. AU - Tanaka, T. AU - Tanaka, K. AU - Hangaishi, A. AU - Mitani, K. PY - 1996 DA - 1996// TI - Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia JO - Leukemia VL - 10 ID - Ogawa1996 ER - TY - JOUR AU - Paquette, R. L. AU - Nicoll, J. AU - Chalukya, M. AU - Elashoff, D. AU - Shah, N. P. AU - Sawyers, C. PY - 2011 DA - 2011// TI - Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors JO - Cancer Genet VL - 204 UR - https://doi.org/10.1016/j.cancergen.2011.06.002 DO - 10.1016/j.cancergen.2011.06.002 ID - Paquette2011 ER - TY - JOUR AU - Sato, T. AU - Goyama, S. AU - Kataoka, K. AU - Nasu, R. AU - Tsuruta-Kishino, T. AU - Kagoya, Y. PY - 2014 DA - 2014// TI - Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia JO - Oncogene VL - 33 UR - https://doi.org/10.1038/onc.2014.108 DO - 10.1038/onc.2014.108 ID - Sato2014 ER - TY - JOUR AU - Theil, K. S. AU - Cotta, C. V. PY - 2014 DA - 2014// TI - The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors JO - Cancer Genet VL - 207 UR - https://doi.org/10.1016/j.cancergen.2014.05.006 DO - 10.1016/j.cancergen.2014.05.006 ID - Theil2014 ER - TY - JOUR AU - Wang, W. AU - Cortes, J. E. AU - Lin, P. AU - Beaty, M. W. AU - Ai, D. AU - Amin, H. M. PY - 2015 DA - 2015// TI - Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors JO - Blood VL - 126 UR - https://doi.org/10.1182/blood-2015-05-646489 DO - 10.1182/blood-2015-05-646489 ID - Wang2015 ER - TY - JOUR AU - Rassi, F. AU - Bergsagel, J. D. AU - Arellano, M. AU - Gaddh, M. AU - Jillella, A. AU - Kota, V. PY - 2015 DA - 2015// TI - Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link? JO - Cancer VL - 121 UR - https://doi.org/10.1002/cncr.29142 DO - 10.1002/cncr.29142 ID - Rassi2015 ER - TY - JOUR AU - Bernstein, R. AU - Bagg, A. AU - Pinto, M. AU - Lewis, D. AU - Mendelow, B. PY - 1986 DA - 1986// TI - Chromosome 3q21 abnormalities associated with hyperactive thrombopoiesis in acute blastic transformation of chronic myeloid leukemia JO - Blood VL - 68 ID - Bernstein1986 ER - TY - JOUR AU - Konantz, M. AU - Andre, M. C. AU - Ebinger, M. AU - Grauer, M. AU - Wang, H. AU - Grzywna, S. PY - 2013 DA - 2013// TI - EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2012.211 DO - 10.1038/leu.2012.211 ID - Konantz2013 ER - TY - JOUR AU - Lugthart, S. AU - Figueroa, M. E. AU - Bindels, E. AU - Skrabanek, L. AU - Valk, P. J. AU - Li, Y. PY - 2011 DA - 2011// TI - Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1 JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-04-281337 DO - 10.1182/blood-2010-04-281337 ID - Lugthart2011 ER - TY - JOUR AU - Barjesteh van Wallwijk van Doorn-Khosrovani, S. AU - Erpelinck, C. AU - Putten, W. L. AU - Valk, P. J. AU - Poel-van de Luytgaarde, S. AU - Hack, R. PY - 2003 DA - 2003// TI - High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients JO - Blood VL - 101 UR - https://doi.org/10.1182/blood-2002-05-1459 DO - 10.1182/blood-2002-05-1459 ID - Barjesteh van Wallwijk van Doorn-Khosrovani2003 ER - TY - JOUR AU - Lugthart, S. AU - Groschel, S. AU - Beverloo, H. B. AU - Kayser, S. AU - Valk, P. J. AU - Zelderen-Bhola, S. L. PY - 2010 DA - 2010// TI - Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.29.2771 DO - 10.1200/JCO.2010.29.2771 ID - Lugthart2010 ER - TY - JOUR AU - Thol, F. AU - Yun, H. AU - Sonntag, A. K. AU - Damm, F. AU - Weissinger, E. M. AU - Krauter, J. PY - 2012 DA - 2012// TI - Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes JO - Ann Hematol VL - 91 UR - https://doi.org/10.1007/s00277-012-1457-7 DO - 10.1007/s00277-012-1457-7 ID - Thol2012 ER - TY - JOUR AU - Daghistani, M. AU - Marin, D. AU - Khorashad, J. S. AU - Wang, L. AU - May, P. C. AU - Paliompeis, C. PY - 2010 DA - 2010// TI - EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2010-01-264234 DO - 10.1182/blood-2010-01-264234 ID - Daghistani2010 ER - TY - JOUR AU - Yeung, D. T. AU - Mauro, M. J. PY - 2014 DA - 2014// TI - Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors JO - Hematology Am Soc Hematol Educ Program VL - 2014 ID - Yeung2014 ER - TY - JOUR AU - Branford, S. AU - Kim, D. W. AU - Soverini, S. AU - Hague, A. AU - Shou, Y. AU - Woodman, R. C. PY - 2012 DA - 2012// TI - Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.40.5217 DO - 10.1200/JCO.2011.40.5217 ID - Branford2012 ER - TY - JOUR AU - Marin, D. AU - Ibrahim, A. R. AU - Lucas, C. AU - Gerrard, G. AU - Wang, L. AU - Szydlo, R. M. PY - 2012 DA - 2012// TI - Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.6565 DO - 10.1200/JCO.2011.38.6565 ID - Marin2012 ER - TY - JOUR AU - Gratwohl, A. AU - Pfirrmann, M. AU - Zander, A. AU - Kroger, N. AU - Beelen, D. AU - Novotny, J. PY - 2016 DA - 2016// TI - Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2015.281 DO - 10.1038/leu.2015.281 ID - Gratwohl2016 ER -